Medicare withholds cost data for senior GLP-1 obesity drugs as Massachusetts sues UnitedHealth

Medicare announced that seniors can obtain Wegovy and Zepbound for $50 a month starting in July, but the agency has not disclosed how much the program will cost taxpayers.

The absence of cost transparency leaves policymakers and insurers uncertain about the budget impact of expanding GLP-1 coverage for obesity treatment.

At the same time, Massachusetts has filed a lawsuit against UnitedHealth, alleging improper handling of the drugs and seeking redress for alleged overcharges.

These developments highlight growing scrutiny of the rapidly expanding GLP-1 market and its financial implications for Medicare and the broader health‑care system.